Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ UBE3B Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA599734
Description
Antibody detects endogenous levels of total UBE3B.
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin-protein ligases. This gene encodes a member of the E3 ubiquitin-conjugating enzyme family which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme and transfers the ubiquitin to the targeted substrates. A HECT (homology to E6-AP C-terminus) domain in the C-terminus of the longer isoform of this protein is the catalytic site of ubiquitin transfer and forms a complex with E2 conjugases. Shorter isoforms of this protein which lack the C-terminal HECT domain are therefore unlikely to bind E2 enzymes. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene.
Specifications
UBE3B | |
Polyclonal | |
Unconjugated | |
UBE3B | |
BPIDS; HECT-type ubiquitin transferase E3B; KOS; UBE3B; UBE3B_v2; ubiquitin protein ligase E3B; ubiquitin-protein ligase E3B | |
Rabbit | |
Affinity chromatography | |
RUO | |
89910 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
Q7Z3V4 | |
UBE3B | |
A synthesized peptide derived from human UBE3B(Accession Q7Z3V4), corresponding to amino acid residues R981-P1031. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction